PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (PMCB) Stock Overview
Explore PharmaCyte Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.5M
P/E Ratio
0.34
EPS (TTM)
$1.34
ROE
0.46%
PMCB Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PharmaCyte Biotech, Inc. (PMCB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.80, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.37.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.34 and a market capitalization of 6.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.